Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.
about
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationTherapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Therapeutic cancer vaccines: are we there yet?Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancementFocusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Effects of 4-1BB signaling on the biological function of murine dendritic cells.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of EomesoderminEomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy4-1BB protects dendritic cells from prostate cancer-induced apoptosis.Delivering safer immunotherapies for cancer.Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung.Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.Contribution of 4-1BBL on radioresistant cells in providing survival signals through 4-1BB expressed on CD8⁺ memory T cells in the bone marrow.4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.
P2860
Q28068378-2A21991E-4085-4E1E-B764-49C20A7B6B9CQ33426409-6E4766E7-43F6-4ED6-9AF6-C662401E7966Q34786691-B3A7A66B-5E1D-49C7-8881-BA90A3F0D4FAQ35382043-505D7623-FF30-4A82-A7F5-24DD14862B89Q35764479-268AEA6B-5935-484F-9F77-BF7DDC652A0CQ35995857-6405A245-BB51-4439-BCFB-637B7B441626Q36597479-D912C5DC-0ACB-4B07-9176-2BDBB2889E10Q36675055-B34D0BCC-8350-4BA9-AE68-0759C1599E47Q36750028-A669B128-2057-44D9-B67A-643838F47D28Q37728543-D00B2AA1-4131-4508-8D61-A977E950ACACQ37948129-F6140EF5-EC28-43C8-BCE4-8619D5090F64Q38081999-F37713F1-DFB2-4701-B47F-D7F2267771A2Q38214095-1F8F6789-EE3C-4DF5-89B4-935BD7FD4A30Q39258569-C334E1D0-650F-42E1-A59A-9083A64B3FA2Q39330984-EE4B90CC-C928-4A00-9CA5-FC0101A964A0Q39706240-48CB9BA4-B5C7-4FA2-B9F5-C1319C8A499FQ40386176-0691EBD4-1CC6-4C56-9A19-C585241D64CAQ42126236-FEC8A013-2F74-4308-9A4B-5A30D413C4F9Q50943160-D2EABAC3-DDB6-4AAA-BE14-C3F43E9848BBQ52880884-2259B3D1-C408-4DC3-98C0-7C646B8829CF
P2860
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluating the cellular target ...... pre-established tumor in mice.
@ast
Evaluating the cellular target ...... pre-established tumor in mice.
@en
type
label
Evaluating the cellular target ...... pre-established tumor in mice.
@ast
Evaluating the cellular target ...... pre-established tumor in mice.
@en
prefLabel
Evaluating the cellular target ...... pre-established tumor in mice.
@ast
Evaluating the cellular target ...... pre-established tumor in mice.
@en
P2093
P2860
P1433
P1476
Evaluating the cellular target ...... pre-established tumor in mice.
@en
P2093
Byoung S Kwon
Gloria H Y Lin
Tania H Watts
Thanuja Ambagala
Yuanqing Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0011003
P407
P577
2010-06-08T00:00:00Z